AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03148639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar therapy
Description: Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
Study NCT03148639 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Avatar therapy
Description: Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
Study NCT03148639 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment-as-usual
Description: Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
Study NCT00140114 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol (Cytotec®)
Description: 50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
Study NCT04710433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive Neuromodulation
Description: Sacral nerve stimulation via two adhesive electrodes (single current).
Study NCT04710433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical and Behavioral Therapy
Description: Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
Study NCT03707730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AGY
Description: oral AGY taken prior to meals
Study NCT03707730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo taken prior to meals
Study NCT02763995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
Study NCT01363076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Single IN dose of 15 mg ketorolac tromethamine for subjects weighing \<50 kg.
Study NCT01363076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
Study NCT01769872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue derived MSCs Transplantation
Description: Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
Study NCT02130011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: with feeding/fluid instruction
Description: No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
Study NCT04483947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
Study NCT04483947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
Study NCT03408145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Injection of 3x 2.5ml of Hyaluronic Acid
Study NCT03408145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Injection of 3x 2.5ml of Hyaluronic Acid
Study NCT03408145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic Tissue Allograft
Description: Injection of 1x 1ml of Amniotic Tissue Allograft
Study NCT03408145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Tissue Allograft
Description: Injection of 1x 1ml of Amniotic Tissue Allograft
Study NCT03408145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Injection of Saline
Study NCT03408145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection of Saline
Study NCT00007501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella-zoster vaccine
Description: Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
Study NCT00007501 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccine
Study NCT00179179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplementation
Description: 2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
Study NCT00179179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
Study NCT01944332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gamete treatment
Description: Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The spermatozoa will be prepared in the standard fashion and utilized for injection or intrauterine insemination after exposure to a membrane permeabilizing agent. Human recombinant PLC-zeta will also be used if the spermatozoa have been confirmed to be PLC-zeta deficient. The injected oocytes will then be exposed to activating agents for the purpose of inducing embryo development. The oocyte activating agent is calcium ionophore and for sperm membrane permeabilization to assist in sperm DNA decondensation is streptolysin O (SLO).
Study NCT01194700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250(8puffs) via Evohaler actuator
Description: 8 puffs of Seretide250/Placebo via Evohaler actuator
Study NCT01194700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250 (8 puffs)/placebo via Volumatic spacer
Description: 8 puffs of Seretide 250/placebo via volumatic spacer
Study NCT01194700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer
Description: Seretide 250/placebo 8 puffs via Aerochamber Plus
Study NCT01194700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo via Synchro-Breathe
Description: Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
Study NCT00791882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
Study NCT00791882 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Social Skills Training
Description: A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
Study NCT04565223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed
Study NCT03995082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome Measure Survey result feedback
Description: Patients will receive a graph of their results from the PROM survey each time they complete a survey
Study NCT01260753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UR-63325
Description: UR-63325
Study NCT01260753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate nasal spray
Description: Fluticasone propionate nasal spray
Study NCT01260753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to UR 63325 and fluticasone propionate nasal spray
Study NCT01183286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CFFONE
Description: A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
Study NCT01183286 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CF website
Description: A CF-related educational website which has some areas of CF information and services relevant to adolescents.
Study NCT03753542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia education, booklet Providence and tele-nursing follow-up
Description: Multimedia education, booklet and weekly tele-nursing follow-up is about chemotherapy and side effects management
Study NCT02388789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active movement
Description: same as arm description
Study NCT03934879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitClub
Description: Participants will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
Study NCT03934879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular School Activities
Description: Students will participate in regular school activities.
Study NCT04725981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Description: Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
Study NCT04725981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total laparoscopic hysterectomy
Description: Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
Study NCT04603248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
Study NCT04350203 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic right colectomy with intracorporeal anastomosis (IA)
Description: First, the right colon dissection was completed by laparoscopy. An isoperistaltic side-to-side ileocolonic mechanical anastomosis was then performed by using a linear cutting stapler. The enterotomy used to enter the stapler was closed with a running suture (3-0 absorbable monofilament or a 3-0 barbed suture). Finally, the specimen was extracted through a Pfannenstiel mini-laparotomy (4-5 cm).
Study NCT04350203 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic right colectomy with extracorporeal anastomosis (EA)
Description: First, the right colon was widely mobilized. A small laparotomy was performed in the mid/upper abdomen to exteriorize the colon and to perform a side-to-side mechanical anastomosis, using a linear cutting stapler (GIA). The bowel opening was closed either with a manual suture or by a second firing of the GIA.
Study NCT00813475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal bolus insulin regimen (tight glucose control)
Description: Basal bolus insulin regimen
Study NCT00813475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal bolus insulin regimen (standard control)
Description: basal bolus insulin regimen
Study NCT02218996 — intervention group
Intervention type: OTHER
Intervention: Psychosocial treatment
Description: Regular psychosocial treatment in clinical outpatient service.
Study NCT02243852 — intervention group
Intervention type: DRUG
Intervention: Growth Hormone Replacement Therapy
Description: An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
Study NCT00844883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib: given 400 mg twice per day for as long as it is beneficial
Study NCT00844883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC Bead-TACE
Description: LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period
Study NCT01625169 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etravirine pharmacokinetics in breast milk and plasma
Description: HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
Study NCT03675399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supra-threshold isometric exercise
Description: The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
Study NCT03675399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infra-threshold isometric exercise
Description: The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
Study NCT03292484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AR101
Description: AR101
Study NCT03390322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiaGone™
Description: Duodenal Glycemic Control™ using the DiaGone™ system
Study NCT04099823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI screening form
Description: Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
Study NCT04099823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urine pregnancy test
Description: Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
Study NCT04099823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MR brain
Description: You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging.
Study NCT06516354 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Portable sleep apnea screening
Description: Screening of stroke and TIA patients on the stroke inpatient unit using theSTOP BANG questionnaire and portable sleep testing (PST) during inpatient hospitalization, early interpretation of PST results by neurology with prescribed treatment upon discharge from hospital
Study NCT04230681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Patients will be randomized to one of two opioids for the treatment of post-operative pain.
Study NCT04230681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl
Study NCT03458520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MR imaging
Description: undergo PET/MR imaging
Study NCT03458520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR imaging
Description: Undergo MR imaging
Study NCT03458520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT imaging
Description: Undergo PET/CT imaging
Study NCT02127762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
Study NCT01660945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01660945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vytorin
Study NCT00878020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, Single Dose, 1 day
Study NCT00878020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0mg, Single Dose, 1 day
Study NCT00878020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
Study NCT00878020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
Study NCT01788423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid
Description: All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
Study NCT01788423 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: hearing aid
Description: All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
Study NCT02498652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5 mg
Description: Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets).
Study NCT02498652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Description: allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
Study NCT02629705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Carrageenan
Description: Carrageenan 250 mg bid supplemented to a standard food
Study NCT02629705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo (Mannitol/Aerosil) bid supplemented to a standard food
Study NCT00133744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
Study NCT00133744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid plus iron
Description: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
Study NCT00133744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplements with multiple vitamins and minerals
Description: pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg